No. 16: Becton, Dickinson (medical segment)
Franklin Lakes, N.J.
2018 revenues: $8,616,000,000
Fiscal year ending: Sept. 30, 2018
Last year’s rank: 16
Vincent Forlenza, chairman & CEO; Thomas Polen, president & COO; Simon Campion, EVP, president, interventional; Alexandre Conroy, EVP, chief integrated supply chain officer; Roland Goette, EVP, president, EMEA; Patrick Kaltenbach, EVP, president, life sciences; Samrat Khichi, EVP, GC, public policy & regulatory affairs; Betty Larson, EVP, chief HR officer; James Lim, EVP, president, Greater Asia; Alberto Mas, EVP, president, medical; Christopher Reidy, EVP, CFO & chief administrative officer; Pierre Boisier, EVP, CQO; Gary Cohen, EVP, global health & president, BD Foundation; John DeFord, EVP, CTO, R&D; George Parr; EVP, chief marketing officer; William Sigmund, EVP, chief medical officer; Linda Tharby, EVP, customer experience; Charles Bodner, SVP, corporate finance & chief accounting officer; Gary DeFazio, SVP, corporate secretary & associate GC; John Gallagher, SVP, treasurer & CFO, medical; Michelle Quinn, SVP, chief ethics & compliance officer; Antoinette Segreto, SVP, taxes; Ami Simunovich, SVP, chief regulatory officer
More than two-thirds of the revenues for BD’s medical segment involved medication delivery and management — important growth drivers for the business. Products in this category include a whole range of catheters, infusion pumps and systems, syringes and needles, medication compounding workflow systems and automated medication dispensing devices. BD (NYSE:BDX) also has a diabetes care business manufacturing syringes, pen needles and other products related to injection or infusion of insulin and other drugs. Its pharmaceutical systems business makes prefillable drug delivery systems including syringes, safety, shielding and self-injection systems. – CN